VEGFR Modulator

Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition.

Casdatifan (AB521) is an orally active and selective allosteric small-molecule inhibitor of hypoxia-inducible factor 2α (HIF-2α). Casdatifan inhibits pro-tumor gene transcription by blocking the heterodimerization of HIF-2α with ARNT, and significantly suppresses tumor growth in clear cell renal cell carcinoma (ccRCC) models either as a monotherapy or in combination with agents such as Zimberelimab (HY-P99109). Casdatifan is applicable for the research of ccRCC.

LM-299 is a bispecific antibody targeting PD-1 and VEGF with anti-tumor activity. The dual binding activity of LM-299 is achieved through the effective binding of its Fab-terminal anti-VEGF-A antibody to human VEGF-A, as well as the blocking effect of its Fc-terminal anti-PD-1 antibody on the PD-1/PD-L1 pathway. LM-299 binds to and modulates PD-1 and VEGF. LM-299 can be used in studies related to advanced malignant tumors, advanced solid tumors, and advanced non-small cell lung cancer.

Rabbit Thrombin is a serine protease. Rabbit Thrombin forms a covalent complex with antithrombin III and reversibly binds endothelial cell surface high-affinity sites. Rabbit Thrombin regulates VEGF and Ang-2, potentiates VEGF mitogenic activity and protects endothelial cells from apoptosis. Rabbit Thrombin can be used for the research of hindlimb ischemia.

Enzyme modulator-1 (example 205) is a potent enzyme modulator that modulates p38, bcr-ab1, and VEGFR. Enzyme modulator-1 can be used for the research of cancer, rheumatoid arthritis, retinopathies including diabetic retinal neuropathy and macular degeneration.